Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease
Authors
Keywords
-
Journal
Modern Rheumatology
Volume 30, Issue 2, Pages 225-231
Publisher
Informa UK Limited
Online
2019-11-21
DOI
10.1080/14397595.2019.1696505
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- (2019) Oliver Distler et al. NEW ENGLAND JOURNAL OF MEDICINE
- CV safety of nintedanib in subgroups by CV risk at baseline in the TOMORROW and INPULSIS trials
- (2019) Imre Noth et al. EUROPEAN RESPIRATORY JOURNAL
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis – Results of a Phase 2 Investigator‐Initiated, Multicenter, Double‐Blind Randomized Placebo‐Controlled Trial
- (2019) Dinesh Khanna et al. Arthritis & Rheumatology
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
- (2019) Kevin R. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
- (2019) Antonella Caminati et al. European Respiratory Review
- Treatment algorithms for systemic sclerosis according to experts
- (2018) Andreu Fernández-Codina et al. Arthritis & Rheumatology
- Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
- (2018) Martin Kolb et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
- (2018) Bruno Crestani et al. Lancet Respiratory Medicine
- Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
- (2018) Elizabeth R Volkmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
- (2017) Frank Hilberg et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis
- (2017) Oliver Distler et al. RESPIRATORY MEDICINE
- Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis
- (2017) Satoshi Ikeda et al. Scientific Reports
- Update of EULAR recommendations for the treatment of systemic sclerosis
- (2016) Otylia Kowal-Bielecka et al. ANNALS OF THE RHEUMATIC DISEASES
- Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
- (2016) M. Kuwana et al. JOURNAL OF RHEUMATOLOGY
- Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
- (2016) Dinesh Khanna et al. LANCET
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
- (2016) Donald P Tashkin et al. Lancet Respiratory Medicine
- Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
- (2015) Jingang Huang et al. ANNALS OF THE RHEUMATIC DISEASES
- Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling
- (2015) Ada Man et al. RHEUMATOLOGY
- Cardiomyopathy in Murine Models of Systemic Sclerosis
- (2015) Paulius Venalis et al. Arthritis & Rheumatology
- Nintedanib: First Global Approval
- (2014) Paul L. McCormack DRUGS
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review: Interstitial Lung Disease Associated With Systemic Sclerosis and Idiopathic Pulmonary Fibrosis: How Similar and Distinct?
- (2014) Erica L. Herzog et al. Arthritis & Rheumatology
- Mutant Soluble Ectodomain of Fibroblast Growth Factor Receptor-2 IIIc Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
- (2012) Zhi-hong Yu et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
- (2011) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
- (2011) M. Reck et al. ANNALS OF ONCOLOGY
- Idiopathic pulmonary fibrosis
- (2011) Talmadge E King et al. LANCET
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension
- (2010) Kohtaro Abe et al. CIRCULATION
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1
- (2008) R. Eferl et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started